-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VOqek6L5Sab2UYc0yriEqpK/6ms1vEGifMtjXB3/zL8dK+oGUwDomgFWhsH6zGJB CWjgaNyMqYnkNdkMpOpnlA== 0000898432-08-000335.txt : 20080403 0000898432-08-000335.hdr.sgml : 20080403 20080403172026 ACCESSION NUMBER: 0000898432-08-000335 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080403 DATE AS OF CHANGE: 20080403 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-60943 FILM NUMBER: 08738391 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13G 1 bvf13g.htm





SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)

INFINITY PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)


 

45665G303

(CUSIP Number)


 

March 25, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

o Rule 13d-1(b)
ý Rule 13d-1(c)
o Rule 13d-1(d)


*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).










 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 2 of 10 Pages


1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund, L.P.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 448,949

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 448,949

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 448,949


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o

 

 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


  2.3%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 


 


 PN

 

 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 3 of 10 Pages


 

1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund II, L.P.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 

 

 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware


 


 

 

 

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 309,000

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 309,000

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 309,000


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o

 

 


 


 


 


11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 1.6%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


PN

 

 

 

 

 

 

 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 4 of 10 Pages



 

1

 

 NAME OF REPORTING PERSON:
BVF Investments, L.L.C.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,070,000

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,070,000


 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 1,070,000


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o

 

 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 5.4%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO


 


 

 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 5 of 10 Pages



 

1

 

 NAME OF REPORTING PERSON:
Investment 10, L.L.C.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Illinois


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 133,000

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 133,000

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 133,000


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o

 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 .7%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO


 


 

 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 6 of 10 Pages



 

1

 

 NAME OF REPORTING PERSON:
BVF Partners L.P.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,960,949

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,960,949

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 1,960,949


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 9.9%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN, HC


 


 

 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 7 of 10 Pages


 

1

 

 NAME OF REPORTING PERSON:
BVF Inc.

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,960,949

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,960,949

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 1,960,949


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 9.9%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 CO, HC


 


 








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 8 of 10 Pages



ITEM 1(a).

NAME OF ISSUER:

INFINITY PHARMACEUTICALS, INC. (“Infinity”)

ITEM 1(b).

ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

780 Memorial Drive

Cambridge, MA  02139



ITEM 2(a).

NAME OF PERSON FILING:

This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

 

(i)

 

 Biotechnology Value Fund, L.P. ("BVF")

 

(ii)

 

 Biotechnology Value Fund II, L.P. ("BVF2")

 

(iii)

 

 BVF Investments, L.L.C. ("Investments")

 

(iv)

 

 Investment 10, L.L.C. ("ILL10")

 

(v)

 

 BVF Partners L.P. ("Partners")

 

(vi)

 

 BVF Inc. ("BVF Inc.")

 

 

 

 

ITEM 2(b).

ADDRESS OF PRINCIPAL BUSINESS OFFICE:

The principal business office of the Reporting Persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

ITEM 2(c).

CITIZENSHIP:

 

 

 BVF:

 a Delaware limited partnership

 

 

 BVF2:

 a Delaware limited partnership

 

 

 Investments:

 a Delaware limited liability company

 

 

 ILL10:

 an Illinois limited liability company

 

 

 Partners:

 a Delaware limited partnership

 

 

 BVF Inc.:

 a Delaware corporation

 

ITEM 2(d).

TITLE OF CLASS OF SECURITIES:

This Schedule 13G is being filed with respect to the common stock, par value $0.001 per share ("Common Stock"), of Infinity.  The Reporting Persons' percentage ownership of Common Stock is based on 19,737,359 shares of Common Stock being outstanding.

As of March 25, 2008, BVF beneficially owned 448,949 shares of Common Stock, BVF2 beneficially owned 309,000 shares of Common Stock, Investments beneficially owned 1,070,000 shares of Common Stock and ILL10 beneficially owned 133,000 shares of Common Stock.  Partners and BVF Inc. may each be deemed to beneficially own 1,960,949 shares of Common Stock.

ITEM 2(e).

CUSIP Number:

45665G303









 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 9 of 10 Pages



ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS:  One of the following

 

 

Not applicable as this Schedule 13G is filed pursuant to Rule 13d-1(c).

ITEM 4.

OWNERSHIP:

 

 

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 8) on this Schedule 13G is hereby incorporated by reference.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

 

 

Not applicable.

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

 

 

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of Common Stock owned by such parties.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

 

 

Mr. Lampert is the owner, sole director and an officer of BVF Inc.  BVF Inc. is the general partner of Partners, which is the general partner of BVF and BVF 2.  Partners is the manager of Investments and is investment adviser to ILL10.

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

 

 

The members of the group making this filing on Schedule 13G are:  Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., Investment 10, L.L.C., BVF Partners L.P. and  BVF Inc.  

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP:

 

 

Not applicable.








 

 

 

 

 

CUSIP No. 45665G303

 

13G

 

Page 10 of 10 Pages



ITEM 10.

CERTIFICATION

 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

 

April 3, 2008


 


 


BIOTECHNOLOGY VALUE FUND, L.P.*


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BIOTECHNOLOGY VALUE FUND II, L.P.*


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BVF INVESTMENTS, L.L.C.*


 


 


By:


 


BVF Partners L.P., its manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
 President




 

 


INVESTMENT 10, L.L.C.*


 


 


By:


 


BVF Partners L.P., its investment manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BVF PARTNERS L.P.*


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 



BVF INC.*


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President



*The Reporting Person disclaims beneficial ownership except to the extent of its pecuniary interest therein.







Exhibit A


JOINT FILING AGREEMENT


The undersigned agree that this Schedule 13G dated April 3, 2008, relating to the common Stock of Infinity, Inc. shall be filed on behalf of the undersigned.

Dated:

 

April 3, 2008



 


 


BIOTECHNOLOGY VALUE FUND, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BIOTECHNOLOGY VALUE FUND II, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BVF INVESTMENTS, L.L.C.


 


 


By:


 


BVF Partners L.P., its manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
 President



 


 




INVESTMENT 10, L.L.C.


 


 


By:


 


BVF Partners L.P., its investment manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 


BVF PARTNERS L.P.


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President


 


 



BVF INC.


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 


 Mark N. Lampert
President









 -----END PRIVACY-ENHANCED MESSAGE-----